Long term safety of GnRH agonist therapy in precocious puberty: An evaluation of reproductive function, bone density and body composition

While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.